Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: A biomarker substudy of the IABP-SHOCK II-trial

European Journal of Heart Failure

Volumn 16, Issue 8, 2014, Pages 880-887

  Fuernau, Georg ^a   Poenisch, Christian ^a   Eitel, Ingo ^a   De Waha, Suzanne ^a   Desch, Steffen ^a   Schuler, Gerhard ^a   Adams, Volker ^a   Werdan, Karl ^b   Zeymer, Uwe ^c   Thiele, Holger ^a,d  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c KLINIKUM LUDWIGSHAFEN   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cardiogenic shock; Growth differentiation factor 15; Myocardial infarction; Osteoprotegerin; Prognosis

Indexed keywords

BIOLOGICAL MARKER; GROWTH DIFFERENTIATION FACTOR 1; OSTEOPROTEGERIN; GDF15 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR 15; TNFRSF11B PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; INTRAAORTIC BALLOON PUMP; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; BLOOD; COMPLICATION; HEART INFARCTION; MIDDLE AGED; MULTIVARIATE ANALYSIS; SHOCK, CARDIOGENIC; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; OSTEOPROTEGERIN; PROGNOSIS; SHOCK, CARDIOGENIC;

EID: 84905699046     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.117     Document Type: Article

References (30)

1. Goldberg RJ, Spencer FA, Gore JM, Lessard D, Yarzebski J,. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009; 119: 1211-1219.
2. Cheng JM, den Uil CA, Hoeks SE, van der Ent M, Jewbali LS, van Domburg RT, Serruys PW,. Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials. Eur Heart J 2009; 30: 2102-2108.
3. Kar B, Gregoric ID, Basra SS, Idelchik GM, Loyalka P,. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol 2011; 57: 688-696.
4. Eitel I, Blase P, Adams V, Hildebrand L, Desch S, Schuler G, Thiele H,. Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance. Heart 2011; 97: 632-640.
5. Omland T, Ueland T, Jansson AM, Persson A, Karlsson T, Smith C, Herlitz J, Aukrust P, Hartford M, Caidahl K,. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol 2008; 51: 627-633.
6. Ren MY, Sui SJ, Zhang Y, Xu FY, Xu XQ, Zhao JJ, Du YM, Liu WH,. Increased plasma osteoprotegerin levels are associated with the presence and severity of acute coronary syndrome. Acta Cardiol 2008; 63: 615-622.
7. Fuernau G, Zaehringer S, Eitel I, de WS, Droppa M, Desch S, Schuler G, Adams V, Thiele H,. Osteoprotegerin in ST-elevation myocardial infarction: prognostic impact and association with markers of myocardial damage by magnetic resonance imaging. Int J Cardiol 2013; 167: 2134-2139.
8. Kempf T, Bjorklund E, Olofsson S, Lindahl B, Allhoff T, Peter T, Tongers J, Wollert KC, Wallentin L,. Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. Eur Heart J 2007; 28: 2858-2865.
9. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N, Lindahl B, Horn-Wichmann R, Brabant G, Simoons ML, Armstrong PW, Califf RM, Drexler H, Wallentin L,. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation 2007; 115: 962-971.
10. Erkol A, Pala S, Kirma C, Oduncu V, Dundar C, Izgi A, Tigen K, Gibson CM,. Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. Am J Cardiol 2011; 107: 857-862.
11. Erkol A, Oduncu V, Pala S, Kizilirmak F, Kilicgedik A, Yilmaz F, Guler A, Karabay CY, Kirma C,. Plasma osteoprotegerin level on admission is associated with no-reflow phenomenon after primary angioplasty and subsequent left ventricular remodeling in patients with acute ST-segment elevation myocardial infarction. Atherosclerosis 2012; 221: 254-259.
12. Wollert KC, Kempf T,. Growth differentiation factor 15 in heart failure: an update. Curr Heart Fail Rep 2012; 9: 337-345.
13. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC,. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010; 122: 1387-1395.
14. Thiele H, Schuler G, Neumann FJ, Hausleiter J, Olbrich HG, Schwarz B, Hennersdorf M, Empen K, Fuernau G, Desch S, de WS, Eitel I, Hambrecht R, Bohm M, Kurowski V, Lauer B, Minden HH, Figulla HR, Braun-Dullaeus RC, Strasser RH, Rochor K, Maier SK, Mollmann H, Schneider S, Ebelt H, Werdan K, Zeymer U,. Intraaortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock: design and rationale of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Am Heart J 2012; 163: 938-945.
15. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Fuhrmann J, Bohm M, Ebelt H, Schneider S, Schuler G, Werdan K,. Intraaortic balloon support for myocardial infarction with cardiogenic shock. N Engl J Med 2012; 367: 1287-1296.
16. Thiele H, Zeymer U, Neumann FJ, Ferenc M, Olbrich HG, Hausleiter J, de WA, Richardt G, Hennersdorf M, Empen K, Fuernau G, Desch S, Eitel I, Hambrecht R, Lauer B, Bohm M, Ebelt H, Schneider S, Werdan K, Schuler G,. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial. Lancet 2013; 382: 1638-1645.
17. Pedersen S, Mogelvang R, Bjerre M, Frystyk J, Flyvbjerg A, Galatius S, Sorensen TB, Iversen A, Hvelplund A, Jensen JS,. Osteoprotegerin predicts long-term outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Cardiology 2012; 123: 31-38.
18. Venuraju SM, Yerramasu A, Corder R, Lahiri A,. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol 2010; 55: 2049-2061.
19. Reynolds HR, Hochman JS,. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008; 117: 686-697.
20. Mangan SH, Van CA, Rush C, Golledge J,. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 2007; 76: 494-505.
21. Link A, Poss J, Rbah R, Barth C, Feth L, Selejan S, Bohm M,. Circulating angiopoietins and cardiovascular mortality in cardiogenic shock. Eur Heart J 2013; 34: 1651-1662.
22. Lok SI, Winkens B, Goldschmeding R, van Geffen AJ, Nous FM, van KJ, van der Weide P, Klopping C, Kirkels JH, Lahpor JR, Doevendans PA, de JN, de Weger RA,. Circulating growth differentiation factor-15 correlates with myocardial fibrosis in patients with non-ischaemic dilated cardiomyopathy and decreases rapidly after left ventricular assist device support. Eur J Heart Fail 2012; 14: 1249-1256.
23. Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC,. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98: 351-360.
24. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC,. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011; 17: 581-588.
25. Senthil S, Veerappan RM, Ramakrishna RM, Pugalendi KV,. Oxidative stress and antioxidants in patients with cardiogenic shock complicating acute myocardial infarction. Clin Chim Acta 2004; 348: 131-137.
26. Han ES, Muller FL, Perez VI, Qi W, Liang H, Xi L, Fu C, Doyle E, Hickey M, Cornell J, Epstein CJ, Roberts LJ, Van RH, Richardson A,. The in vivo gene expression signature of oxidative stress. Physiol Genomics 2008; 34: 112-126.
27. Zimmers TA, Jin X, Hsiao EC, Perez EA, Pierce RH, Chavin KD, Koniaris LG,. Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. J Surg Res 2006; 130: 45-51.
28. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koniaris LG,. Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury. Shock 2005; 23: 543-548.
29. Heringlake M, Charitos EI, Gatz N, Kabler JH, Beilharz A, Holz D, Schon J, Paarmann H, Petersen M, Hanke T,. Growth differentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients. J Am Coll Cardiol 2013; 61: 672-681.
30. Wallentin L, Zethelius B, Berglund L, Eggers KM, Lind L, Lindahl B, Wollert KC, Siegbahn A,. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One 2013; 8 e78797.